HIGH DOSE RITUXIMAB IN COMBINATION WITH AUTOLOGOUS STEM-CELL TRANSPLANTATION (BEFORE AND AFTER) FOR RELAPSED AGGRESSIVE B-CELL NON-HODGKIN'S LYMPHOMAS.

HIGH DOSE RITUXIMAB IN COMBINATION WITH AUTOLOGOUS STEM-CELL TRANSPLANTATION (BEFORE AND AFTER) FOR RELAPSED AGGRESSIVE B-CELL NON-HODGKIN'S LYMPHOMAS

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-ONRC-14005106

Enrollment

Unknown

Registered

2014-08-06

Start date

2006-01-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

B cell lymphoma

Interventions

1:autologous stem cell transplantation

2:rituximab combined with autologous stem cell transplantation

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Eligible patients were age 18 to 65 years and had aggressive CD20 B-cell non-Hodgkin's lymphoma, and had experienced relapse or did not achieve CR with a standard anthracycline-based regimen. Before enrollment, CD20 aggressive B-cell lymphoma was histologically con?rmed in all patients. Eligible patients had a WHO performance status of 0 to 1, sensitive to chemotherapy,normal heart function,renal function and liver function.

Exclusion criteria

Exclusion criteria: Exclusion criteria included: 1. CNS involvement; 2. history of HIV infection; 3. post-transplantation lymphoproliferative disorder; 4. previous organ transplant and pregnancy; 5. allergic to rituximab; 6. The patients disagree to join this study; 7. Any factor that interfere the patient to participate or complete the study.

Design outcomes

Primary

Measure	Time frame
3 year overall survival rate;3 year disease free survival rate;recovery of the neutrophil and platelet count;Immune Reconstitution;prognosis factor;	—

Countries

China

Contacts

Public ContactYu Kang

yukang62@126.com+86 13806681379

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026